REGN Deadline: REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - The Rosen Law Firm is reminding investors who purchased Regeneron Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 10, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Regeneron - The lawsuit alleges that Regeneron made false and misleading statements regarding its business practices, particularly related to its product Eylea [5]. - Specific allegations include that Regeneron paid credit card fees to distributors to prevent them from charging customers more for using credit cards, which effectively subsidized the prices for Eylea [5]. - The lawsuit claims that these actions misled investors about the true sales figures and pricing strategies of Regeneron, resulting in damages when the true information was revealed [5].